Researchers found that erythropoietin administration can prevent acute cardiotoxic effects induced by chemotherapy agents doxorubicin and trastuzumab. The study suggests that rhEPO may be used to reduce acute cardiotoxic effects during chemotherapy, potentially preventing long-term development of cardiomyopathy.
A joint study will assess changes in brain structure and cognitive functions in adult cancer patients treated with chemotherapy. Researchers hope to identify neuroprotective agents to prevent chemotherapy-related cognitive dysfunction, a condition affecting many cancer patients.
The QUASAR trial found that chemotherapy with fluorouracil and folinic acid reduces the risk of recurrence by 22% and death by 18% in patients with stage II colorectal cancer. The absolute improvements are small, but still significant.
Researchers at the University of Texas M. D. Anderson Cancer Center report that a milder chemotherapy regimen before stem cell transplant resulted in complete remission for 45 of 47 patients with relapsed follicular lymphoma. Long-term follow-up showed improved overall survival and progression-free survival rates.
Researchers found that simultaneous treatment resulted in a five-year survival rate of 15.1 percent, compared to 10.6 percent with sequential therapy. The study's findings suggest that concurrent chemotherapy and radiation is the new standard of care for locally advanced non-small cell lung cancer.
Researchers found that quantitative index adds accurate information about patients' responses to first-line chemotherapy, improving tumor response prediction. This method can also identify disease transformation and shorten treatment for favorable responders.
Researchers examined the effectiveness of intra-arterial combination chemotherapy in treating advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). The treatment led to a median survival time of 457.2 days and a one-year survival rate of 70%.
A recent study found that women with HER-2 positive breast cancer who receive Taxol alongside chemotherapy experience improved survival rates. In contrast, estrogen-receptor-positive and HER-2-negative patients do not benefit from the added treatment, offering a targeted approach to personalized medicine.
Research suggests that young women with estrogen receptor-positive (ER+) breast cancer who undergo adjuvant chemotherapy do not experience higher survival rates than those with ER-negative tumors. The study, published in Breast Cancer Research, found a 5% difference in survival rates between the two groups.
A new study found that cancer patients receiving chemotherapy did not notice restrictions in their treatment access following the enactment of the Medicare Prescription Drug, Improvement and Modernization Act. Despite significant reductions in government reimbursement to oncologists, patients perceived no barriers to their care.
A new study found that gemcitabine chemotherapy after surgery doubles disease-free survival from 4.9 to 11.4 months in patients with operable pancreatic cancer, improving outcomes by 41 percent
Research shows PET scans with fluorodeoxyglucose (FDG) can predict a breast tumor's response to chemotherapy and a patient's likelihood of survival. Women with high initial FDG uptake and significant reduction after treatment are more likely to achieve complete response.
A new method of molecular profiling has accurately predicted which stage II colon cancer patients are most likely to have their disease recur after surgery. The analysis identified two groups with distinct clinical outcomes, allowing for more accurate selection of patients who would benefit from adjuvant chemotherapy.
Scientists have developed a method to detect circulating tumour cells (CTCs) in blood before and after chemotherapy treatment, potentially identifying patients at risk of cancer recurrence. The study found that CTCs persisted in the blood of patients who were more likely to experience recurrence.
A new study finds breast cancer survivors who received both chemotherapy and radiotherapy reported the most severe and prolonged fatigue. The study, published in CANCER, a peer-reviewed journal of the American Cancer Society, found women who received both treatments experienced more days with reported fatigue at each assessment.
Two studies found that exercise and yoga can improve quality of life in women with early-stage breast cancer by increasing physical fitness and self-esteem. Yoga was particularly beneficial for women not receiving chemotherapy, promoting better social well-being and overall quality of life.
A common molecular pathway called retinoblastoma (RB) tumor suppressor could help predict which lung cancer patients will benefit from chemotherapy drugs. Researchers found that turning off the RB pathway resulted in an altered response to chemotherapy agents and more cancer cell death.
A study published in the Journal of the National Cancer Institute found that chemotherapy with bevacizumab increases the risk of blood clots in arteries, with a higher incidence among patients over 65 years old. The risk of arterial thromboembolic events was significantly higher in patients treated with the combination therapy compared...
Researchers at MGH confirm that bone marrow transplantation after chemotherapy restores fertility in female mice, with donor-derived egg cells observed but not involved in fertilization. The study also reveals that resuming mating and bone marrow transplants shortly after chemotherapy improve fertility rates.
A study led by Duke University researchers found that a white blood cell booster can significantly reduce the risk of chemotherapy-related complications characterized by fever and low white blood cell levels. The study, published in the Journal of Clinical Oncology, involved over 3,000 patients and showed that patients taking the drug ...
Testicular cancer patients with metastatic disease can be cured with high-dose chemotherapy and a stem cell transplant, as shown in an Indiana University School of Medicine report. The treatment, which involves carboplatin chemotherapy at five times the standard dosage, has a success rate of over 90%.
A recent meta-analysis confirms that combining trastuzumab with chemotherapy reduces mortality by -34% and increases disease-free survival by 38% in women with operable HER-2 positive breast cancer. This treatment strategy also decreases the risk of locoregional and distant recurrences.
A pilot study found that gonadotropin-releasing hormone antagonists can suppress ovarian function in women receiving chemotherapy, protecting their fertility. The treatment was well-tolerated with minimal side effects and restored ovarian function after chemotherapy stopped.
A review of nine randomized trials shows that patients treated with cisplatin lived slightly longer than those treated with carboplatin, with a median survival of 9.1 months compared to 8.4 months. However, the difference in survival was not statistically significant for all patient groups.
Four-year data from two large clinical trials found that trastuzumab significantly improves disease-free survival and overall survival rates in women with HER2-positive breast cancer. The study showed a 52% decrease in the risk of disease recurrence and a 35% reduction in mortality rates compared to chemotherapy alone.
A trial found that circulating tumor cells in the blood of patients with metastatic prostate cancer can predict how well they will respond to chemotherapy. Patients with more than five tumor cells per blood sample had a worse prognosis, while those whose CTC number went down fared better.
A recent study published by researchers at Duke University Medical Center and The University of Texas M. D. Anderson Cancer Center has found that chemotherapy may actually enhance the effectiveness of cancer vaccines used to treat brain tumors. The process by which immune cells regenerate after being wiped out by chemotherapy makes the...
A study of 519 patients found no benefit in overall survival from pre-operative chemotherapy for nonsmall cell lung cancer. Neo-adjuvant therapy did result in tumor down-staging and improved response rates, but its use should be targeted towards specific patient subgroups.
Patients with liver cancer undergoing chemotherapy who have high serum levels of hepatitis B virus (HBV) DNA are at risk of developing severe hepatitis, which is associated with poor survival. Researchers found that a pre-chemotherapy HBV viral load above 10^5.65 copies per milliliter was linked to poorer outcomes.
A recent study has found that the gene p53, which is thought to assist chemotherapy in killing cancer cells, may actually help them thrive. In contrast, patients with normal p53 had only a 30% survival rate after five years. The research suggests that inhibiting p53 in tumors during chemotherapy could improve patients' long-term survival.
Researchers found that FDG-PET imaging can identify patients who respond to chemotherapy, allowing for early termination of futile treatment. This improves patient care by providing an alternative approach, such as stopping chemotherapy or switching to a more adequate therapeutic option.
Researchers found that combining a diabetes drug with platinum-based chemotherapy boosted its potency in various cancer cell lines and mouse tumors. The combination halted or shrunk tumors up to three times more effectively than either drug alone.
A phase III trial of darbepoetin alfa found that the drug did not reduce blood transfusion risk in non-chemotherapy patients, but increased overall patient mortality. Patients with certain types of cancer saw better survival outcomes when treated with the drug.
Researchers used a high-throughput technology to screen human genes for biological activity and identified 87 genes that affect chemotherapy drug paclitaxel's sensitivity in lung-cancer cells. Blocking these genes increased cell sensitivity by up to 10,000 times.
Patients undergoing minimally invasive lung cancer surgery experience shorter hospital stays and accelerated recovery times compared to traditional open surgery. This approach also improves chemotherapy delivery, reducing delays and increasing treatment efficacy.
Early-stage breast cancer patients who receive a single method of treatment, such as tamoxifen or chemotherapy, have improved survival rates. Chemotherapy shows modest yet sustained benefits in relapse-free and overall survival, particularly in younger women and those without ovarian suppression.
According to a randomized controlled trial, radiation therapy is the preferred treatment option for patients with locally advanced stage IIIA-N2 non-small-cell lung cancer who have responded to chemotherapy. This finding suggests that surgery may not improve survival rates compared to radiation after chemotherapy treatment.
A phase III clinical trial found that the first antisense drug, oblimersen, improved response rates in CLL patients who remained sensitive to chemotherapy drug fludarabine. The study showed a four-fold increase in 'CR/nPR' in these patients compared to those no longer responding to fludarabine.
A study published in the Journal of the National Cancer Institute found that women with breast cancer who received growth factors during chemotherapy had a higher risk of developing leukemia or myelodysplastic syndrome. The absolute risk is small, but it should be considered when making treatment decisions.
Obese and less educated women with breast cancer are more likely to receive reduced chemotherapy doses, threatening their survival. Research shows that doctors often reduce doses for these patients without solid medical basis, highlighting treatment disparities in cancer care.
A new study found that breast cancer patients with lower household income and less education are more likely to receive reduced doses of chemotherapy. Severely obese women were four times as likely to receive a reduced dose, while those with less than a high school education were three times as likely.
A randomized trial found that increasing chemotherapy dose intensity did not improve survival rates in patients with osteosarcoma. However, the dose-intensive regimen showed better tumor cell death and lower risks of certain side effects. The study challenges the use of histologic response as a key predictor factor for treatment outcomes.
A study found that chemotherapy with gemcitabine significantly delayed cancer recurrence in patients following pancreatic cancer surgery. The estimated median disease-free survival was 13.4 months for the gemcitabine group compared to 6.9 months for those without chemotherapy.
A survey of 54 cancer centers found few organizations have standardized prescribing practices for oral chemotherapy, with variations in prescription generation and required information. The study highlights the importance of forging a consensus on standardized safeguards and practices for prescribing and monitoring oral chemotherapies.
A study at the University of Texas M.D. Anderson Cancer Center found that combining cromolyn with chemotherapy reduced pancreatic tumor growth by 85% compared to control animals. The combination also increased the effectiveness of standard chemotherapy.
Researchers developed genomic tests to predict breast cancer response to chemotherapy and hormonal therapy, with promising results in clinical trials. The tests showed high accuracy in predicting treatment response and patient outcomes, offering new hope for personalized treatment planning.
Avastin, an anti-angiogenic therapeutic, improves lung cancer patient survival by 20% and reduces side effects compared to conventional chemotherapy. The drug targets tumor blood vessels, enabling chemotherapy drugs to diffuse into the tumor more effectively.
Researchers found significant regions of the brain associated with memory, analysis, and cognitive functions were smaller in breast cancer patients who received chemotherapy compared to those who did not. However, these structural changes were not sustained after three years.
A study found that radiation after surgery and chemotherapy improves overall survival in non-small cell lung cancer patients with lymph node involvement. Patients who received radiation lived almost two years longer than those without radiation.
A consensus statement published in Annals of Surgical Oncology calls for heated chemotherapy after colon cancer surgery to optimize patient survival. The treatment, known as HIPEC, has shown promising results with a median survival of greater than 20 months compared to six-month survival with traditional intravenous chemotherapy.
A panel of genomic tests analyzes a cancerous tumor's molecular traits to determine the most effective chemotherapy, potentially saving lives and reducing toxic side effects. The tests show 80% accuracy in predicting which drugs will kill the tumor.
Researchers at Johns Hopkins have found that lung cancer cells exploit the NRF2 gene to detoxify chemicals, including chemotherapy agents, rendering them ineffective. This discovery may lead to new treatment strategies by blocking NRF2 activity, potentially improving standard chemotherapy drug efficacy.
A new UCLA study shows that chemotherapy causes persistent changes in brain function, leading to cognitive symptoms like forgetfulness and confusion. PET scans reveal a link between chemo-brain symptoms and lower brain metabolism, suggesting that monitoring brain activity could help prevent these effects.
Researchers found that KEAP1 mutations in lung cancer cells increase NRF2 activity, leading to chemotherapy resistance. Meanwhile, a new study suggests targeting school-aged children for flu vaccination could help contain outbreaks.
A new approach to radiotherapy and chemotherapy has significantly improved the outcome for children with high-risk medulloblastoma. The study found that this adaptive treatment can cure over 70% of children with this disease.
Researchers at USC/Norris Comprehensive Cancer Center discovered a new biological marker in tumors that can indicate whether a woman's breast cancer will respond to chemotherapy. Women with high levels of GRP78 protein in their tumors are more likely to have cancer recurrence, but may benefit from additional taxane treatment.
A recent study suggests that young breast cancer patients who receive chemotherapy may experience a higher number of serious side effects than previously reported. These side effects result in significantly higher healthcare expenditures for the affected individuals.
Researchers found that younger women with breast cancer are at risk of experiencing more chemotherapy-related serious adverse effects, including fever, infection, and low blood cell counts. These adverse effects can lead to hospitalizations, emergency room visits, and increased healthcare costs.
Researchers at Massachusetts General Hospital have identified potential ovarian cancer stem cells, which may be responsible for tumor recurrence and resistance to chemotherapy. These stem-like cells were found in mouse and human ovarian cancer lines, and were sensitive to certain treatment approaches.
A study found that HtrA1 protein contributes to chemotherapy resistance in ovarian and gastric cancers by inducing cell death, while ghrelin hormone promotes the storage of energy as fat by altering gene expression in adipose cells. The findings suggest potential therapeutic targets for obesity treatment.